BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25904138)

  • 1. Noncoding RNAs that associate with YB-1 alter proliferation in prostate cancer cells.
    Liu TT; Arango-Argoty G; Li Z; Lin Y; Kim SW; Dueck A; Ozsolak F; Monaghan AP; Meister G; DeFranco DB; John B
    RNA; 2015 Jun; 21(6):1159-72. PubMed ID: 25904138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Links between the oncoprotein YB-1 and small non-coding RNAs in breast cancer.
    Blenkiron C; Hurley DG; Fitzgerald S; Print CG; Lasham A
    PLoS One; 2013; 8(11):e80171. PubMed ID: 24260353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression.
    Imada K; Shiota M; Kohashi K; Kuroiwa K; Song Y; Sugimoto M; Naito S; Oda Y
    Clin Cancer Res; 2013 Sep; 19(17):4638-50. PubMed ID: 23838318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of Y-box-binding protein (YB)-1 and C-X-C motif chemokine ligand 14 (CXCL14) in the progression of prostate cancer via extracellular-signal-regulated kinase (ERK) signaling.
    Wang C; Zhao N; Sato F; Tanimoto K; Okada H; Liu Y; Bhawal UK
    Bioengineered; 2021 Dec; 12(2):9128-9139. PubMed ID: 34696665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence.
    Sheridan CM; Grogan TR; Nguyen HG; Galet C; Rettig MB; Hsieh AC; Ruggero D
    Oncotarget; 2015 Apr; 6(10):7470-80. PubMed ID: 25797255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.
    Law JH; Li Y; To K; Wang M; Astanehe A; Lambie K; Dhillon J; Jones SJ; Gleave ME; Eaves CJ; Dunn SE
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism.
    Xu S; Wang T; Song W; Jiang T; Zhang F; Yin Y; Jiang SW; Wu K; Yu Z; Wang C; Chen K
    Sci Rep; 2015 Aug; 5():13528. PubMed ID: 26314494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
    Imada K; Shiota M; Kuroiwa K; Sugimoto M; Abe T; Kohashi K; Yokomizo A; Eto M; Naito S; Oda Y
    Prostate; 2017 Feb; 77(2):145-153. PubMed ID: 27699813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
    Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
    IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin.
    Khan MI; Adhami VM; Lall RK; Sechi M; Joshi DC; Haidar OM; Syed DN; Siddiqui IA; Chiu SY; Mukhtar H
    Oncotarget; 2014 May; 5(9):2462-74. PubMed ID: 24770864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
    Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
    Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
    Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
    World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide analysis of YB-1-RNA interactions reveals a novel role of YB-1 in miRNA processing in glioblastoma multiforme.
    Wu SL; Fu X; Huang J; Jia TT; Zong FY; Mu SR; Zhu H; Yan Y; Qiu S; Wu Q; Yan W; Peng Y; Chen J; Hui J
    Nucleic Acids Res; 2015 Sep; 43(17):8516-28. PubMed ID: 26240386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
    Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
    Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.
    Shiota M; Zoubeidi A; Kumano M; Beraldi E; Naito S; Nelson CC; Sorensen PH; Gleave ME
    Mol Cancer Res; 2011 Dec; 9(12):1755-66. PubMed ID: 21987172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.
    Yu YN; Yip GW; Tan PH; Thike AA; Matsumoto K; Tsujimoto M; Bay BH
    Int J Oncol; 2010 Aug; 37(2):483-92. PubMed ID: 20596676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC-Activated LncRNA
    Wu QN; Luo XJ; Liu J; Lu YX; Wang Y; Qi J; Liu ZX; Huang QT; Liu ZK; Lu JB; Jin Y; Pu HY; Hu PS; Zheng JB; Zeng ZL; Ju HQ; Xie D; Zhao Q; Xu R
    Cancer Res; 2021 May; 81(10):2636-2650. PubMed ID: 33782099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma.
    Fujiwara-Okada Y; Matsumoto Y; Fukushi J; Setsu N; Matsuura S; Kamura S; Fujiwara T; Iida K; Hatano M; Nabeshima A; Yamada H; Ono M; Oda Y; Iwamoto Y
    Br J Cancer; 2013 Mar; 108(4):836-47. PubMed ID: 23462806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
    Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
    Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.